Peter Sandercock and IST-3

Acute ischemic stroke is a major public health burden and globally a common cause of death and disability

Subtitle: Acute ischemic stroke is a major public health burden and globally a common cause of death and disability
Summary: Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.
Author: International Journal of Stroke; Category: Science; Explicit: No

Track Listing

International Journal of Stroke / Peter Sandercock and IST-3	0:12:54	64kbps	44100	5.91 MB
Acute ischemic stroke is a major public health burden and globally a common cause of death and disability. Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock. keywords:

copy and paste this link in your podcast software:
https://wiley-blackwell.jellycast.com/podcast/feed/25